Teleflex
TFX
$139.67
+1.42%
Teleflex Incorporated is a global medical technology company that designs, develops, and supplies medical devices for hospitals and healthcare providers, focusing on high-acuity procedures across segments including Americas, EMEA, and Asia. The company is a niche player in interventional and surgical instruments, with a diverse portfolio spanning anesthesia, emergency medicine, urology, and vascular access. Currently, the stock is at the center of a turnaround narrative, driven by activist pressure to explore a sale, a potential buyout offer, and a strategic restructuring aimed at reversing years of underperformance. Investors are debating whether the company's deep-value positioning and operational overhaul can revive growth, or if the recent financial weakness and regulatory overhangs will persist.…
TFX
Teleflex
$139.67
Related headlines
Investment Opinion: Should I buy TFX Today?
Based on the analysis, I rate Teleflex as a Hold. The stock offers a deep-value opportunity with a PS ratio of 2.73 versus the industry average of 15.14, and the forward PE of 12.68 suggests the market expects a significant earnings recovery. However, the recent revenue decline and negative profitability warrant caution. The analyst consensus is 'hold' with an average target of $152.55, implying 9.9% upside, which is modest.
Sign up to view all
TFX 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The deep valuation and potential for a buyout provide upside, but the recent revenue collapse and negative profitability create significant downside risk. The stock is a high-risk, high-reward contrarian play. I would upgrade to bullish if revenue growth turns positive and the company posts a profitable quarter, or if a buyout offer is confirmed. I would downgrade to bearish if the revenue decline accelerates or the sale process fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Teleflex's 12-month outlook, with a consensus price target around $153.55 and implied upside of +9.9% versus the current price.
Average Target
$153.55
0 analysts
Implied Upside
+9.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$138 - $170
Analyst target range
Teleflex is covered by 11 analysts, with a consensus recommendation of 'hold' and a mean rating of 2.54 (where 1 is strong buy and 5 is sell). The average target price is $152.55, implying an upside of 9.9% from the current price of $138.83. The distribution of ratings is not provided, but the 'hold' consensus suggests a neutral stance, with some analysts seeing value but not enough conviction to issue buy ratings. The recent institutional ratings show a mix of actions, including an upgrade from Raymond James from Market Perform to Outperform in March 2026, and a Buy from Needham in January 2026, indicating some positive momentum in sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: TFX Investment Factors
Teleflex presents a classic deep-value versus value-trap debate. The bull case rests on a compelling valuation (PS 2.73 vs. industry 15.14), activist-driven strategic alternatives, and a projected earnings recovery (forward PE 12.68). However, the bear case is equally strong, with a 28.47% revenue decline in Q4 2025, negative net income, and persistent underperformance versus the market. Currently, the bearish evidence is slightly more compelling given the recent financial deterioration, but the potential for a buyout or successful restructuring could quickly shift the balance. The single most important tension is whether the Q4 revenue collapse is a one-time event or the start of a structural decline—this will determine if the stock is a bargain or a trap.
Bullish
- Deep value with 82% PS discount: Teleflex trades at a price-to-sales ratio of 2.73, an 82% discount to the industry average of 15.14. This deep-value positioning suggests the market is pricing in significant pessimism, providing a margin of safety for contrarian investors.
- Activist pressure and potential buyout: An activist investor is urging the board to explore a sale, and a potential buyout offer has already caused an 8% pre-market surge. A successful sale could unlock substantial shareholder value, with the stock currently trading at $138.83, near its 52-week high of $145.
- Forward PE implies earnings recovery: The forward PE of 12.68 suggests the market expects a sharp earnings rebound, with estimated EPS of $14.24 for the next fiscal year. If achieved, this would represent a dramatic turnaround from the current negative trailing EPS of -$0.17.
- Positive analyst momentum: Recent upgrades from Raymond James (to Outperform) and Needham (Buy) indicate improving sentiment. The average analyst target of $152.55 implies 9.9% upside, and the low target of $138 is near the current price, suggesting limited downside risk from a consensus perspective.
Bearish
- Revenue collapse in Q4 2025: Q4 2025 revenue plunged 28.47% year-over-year to $568.98 million, a sharp reversal from the growth seen in earlier quarters. This deceleration raises serious questions about demand and competitive positioning.
- Negative profitability and EPS: Trailing twelve-month EPS is -$0.17, and Q4 2025 net income was -$714.33 million, resulting in a net margin of -125.5%. The company is burning cash and struggling to generate consistent profits.
- Underperformance vs. S&P 500: Over the past year, TFX gained 11.41% versus the S&P 500's 20.48%, a relative underperformance of -9.07%. This suggests the market remains skeptical of the turnaround narrative.
- High short interest and low conviction: The short ratio of 6.95 indicates significant bearish positioning, and the consensus rating is 'hold' with a mean score of 2.54, reflecting a lack of strong conviction among analysts.
TFX Technical Analysis
Teleflex's price trend over the past year shows a recovery from a significant drawdown, with the stock up 11.41% over the last 12 months, though it has underperformed the S&P 500's 20.48% gain. The current price of $138.83 sits at 95.7% of its 52-week range (low $100.18, high $145.00), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The 52-week low was set in early 2026, and the stock has since rallied, but the relative strength versus the S&P 500 over the past year is negative at -9.07%, highlighting that the recovery has lagged the broader market.
Beta
0.81
0.81x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$100-$145
Price range past year
Annual Return
+10.7%
Cumulative gain past year
| Period | TFX Return | S&P 500 |
|---|---|---|
| 1m | +3.7% | +5.5% |
| 3m | +8.6% | +1.7% |
| 6m | +14.4% | +12.2% |
| 1y | +10.7% | +18.6% |
| ytd | +14.1% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TFX Fundamental Analysis
Teleflex's revenue trajectory has been volatile, with the most recent quarter (Q4 2025) showing revenue of $568.98 million, a significant decline of 28.47% year-over-year, and a sharp drop from the prior quarter's $913.02 million. This deceleration is concerning, as it marks a reversal from the modest growth seen in earlier quarters of 2025 (Q1: $700.67M, Q2: $780.89M, Q3: $913.02M). The company's gross margin in Q4 2025 was 54.03%, down from 55.28% in Q2 2025, indicating slight margin compression. The revenue decline is likely driven by weakness in key segments, as the latest segment data shows Vascular Access contributing $358.81 million, Interventional $73.80 million, and Surgical $75.45 million, but without historical comparison, the drag is unclear.
Quarterly Revenue
$568984000.0B
2025-12
Revenue YoY Growth
-28.5%
YoY Comparison
Gross Margin
54.0%
Latest Quarter
Free Cash Flow
$245441000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TFX Overvalued?
Given that Teleflex's trailing twelve-month net income is negative (EPS of -$0.17), the price-to-earnings ratio is not meaningful, so I selected the price-to-sales (PS) ratio as the primary valuation metric. The current PS ratio is 2.73, which is a significant discount to the industry average of 15.14 (based on historical data from Q4 2023), indicating the stock trades at an 82% discount to its sector. The forward PE of 12.68 suggests the market expects a sharp earnings recovery, as the company is projected to return to profitability, with estimated EPS of $14.24 for the next fiscal year. This implies a PEG ratio of 0.004, which is extremely low, but this is distorted by the negative trailing earnings and may not be reliable.
PE
-6.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~94x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated. Teleflex's debt-to-equity ratio of 0.87 indicates a moderate leverage level, but the negative net margin of -125.5% in Q4 2025 and negative TTM EPS of -$0.17 highlight severe profitability issues. The company's free cash flow of $245.44 million is positive, but it may not be sufficient to cover debt obligations if losses persist. Revenue concentration in the Americas segment (which generates the majority of sales) exposes the company to regional healthcare policy changes and reimbursement cuts. The sharp 28.47% YoY revenue decline in Q4 2025 suggests potential loss of market share or demand weakness, which could worsen if not addressed.
